Howe & Rusling’s Definium Therapeutics DFTX Stock Holding History

Howe & Rusling’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-31	Closed	-$1K	–	1039
2021 Q3	$1K	Buy	31 +26	+520%	+$1.12K	﹤0.01%	928
2021 Q2	$0	Buy	+5	New	+$262	﹤0.01%	1000

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Howe & Rusling's DFTX Position: Q4 2021 in Review

Howe & Rusling sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 31 shares — an estimated $1K sold.

Howe & Rusling first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

Howe & Rusling reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
Howe & Rusling sold 31 Definium Therapeutics shares in Q4 2021, an estimated $1K.
Howe & Rusling first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
Howe & Rusling's Definium Therapeutics position peaked at $1K in Q3 2021.
176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Howe & Rusling's 13F filing for Q4 2021, filed 14 Feb 2022.